| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P2093 | author name string | J Whitton | |
| G Giordano | |||
| R Lever | |||
| P S Whitton | |||
| N Rampersaud | |||
| A Harkavyi | |||
| P2860 | cites work | Brain-derived neurotrophic factor messenger RNA is expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of adult rat brain and is increased by osmotic stimulation in the paraventricular nucleus | Q61643489 |
| Acute and chronic effects of 4-chloroamphetamine on monoamine metabolism in the rat brain | Q67441060 | ||
| Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice | Q71583548 | ||
| Early diagnosis of Parkinson's disease | Q80194831 | ||
| Depression research: where are we now? | Q21198902 | ||
| Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease | Q24647189 | ||
| Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein | Q26269955 | ||
| Emotion circuits in the brain | Q27860733 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Tyrosine hydroxylase phosphorylation: regulation and consequences | Q28295531 | ||
| Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis | Q28481242 | ||
| Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| Parkinson's disease | Q29616302 | ||
| Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models | Q30497021 | ||
| Cortical networks of procedural learning: evidence from cerebellar damage | Q30542121 | ||
| Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry | Q30975753 | ||
| Etiology and pathogenesis of Parkinson's disease | Q33593402 | ||
| Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity | Q33617472 | ||
| Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? | Q33660662 | ||
| Role of norepinephrine in the pathophysiology and treatment of mood disorders | Q33772708 | ||
| Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease | Q33952130 | ||
| Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells | Q34028497 | ||
| Increased risk of Parkinson's disease after depression: a retrospective cohort study | Q34130645 | ||
| Learning and memory functions of the Basal Ganglia | Q34132332 | ||
| Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system | Q34395267 | ||
| Depression in Parkinson's disease -- a review | Q34478301 | ||
| A systematic review of depression and mental illness preceding Parkinson's disease | Q34502729 | ||
| Brain serotonin transporter binding in non-depressed patients with Parkinson's disease | Q34619565 | ||
| Procedural learning and neostriatal dysfunction in man. | Q34684107 | ||
| Spared caudal brainstem SERT binding in early Parkinson's disease | Q34724279 | ||
| Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease | Q34733143 | ||
| The neuropathological basis for depression in Parkinson's disease | Q34764454 | ||
| Noradrenaline and Parkinson's disease | Q35013240 | ||
| Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. | Q46346508 | ||
| Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations | Q46531059 | ||
| The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. | Q46619925 | ||
| Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model | Q46706492 | ||
| Central serotonin depletion affects rat brain areas differently: a qualitative and quantitative comparison between different treatment schemes | Q46742923 | ||
| Influence of noradrenaline denervation on MPTP-induced deficits in mice | Q46857343 | ||
| Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. | Q48170542 | ||
| The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. | Q48263467 | ||
| Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. | Q48306367 | ||
| Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease. | Q48309761 | ||
| Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. | Q48617135 | ||
| Cognitive deficits in the early stages of Parkinson's disease. | Q48800336 | ||
| Differential age-related loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic suicides. | Q48903836 | ||
| Mesolimbic and mesocortical dopaminergic neurons are necessary for normal exploratory behavior in rats. | Q49160355 | ||
| The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. | Q50662877 | ||
| Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. | Q51978130 | ||
| Does the behavioral "despair" test measure "despair"? | Q52263149 | ||
| Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. | Q53187673 | ||
| Serotonergic dysfunction in Parkinson's disease and its relevance to disability. | Q53188615 | ||
| Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. | Q55044523 | ||
| PET imaging of neocortical monoaminergic terminals in Parkinson's disease | Q59858909 | ||
| Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study | Q60643572 | ||
| Disease model: Parkinson's disease. | Q35203031 | ||
| Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. | Q35209949 | ||
| Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons | Q35320973 | ||
| A new Alzheimer's disease interventive strategy: GLP-1. | Q35843402 | ||
| Non-motor symptoms of Parkinson's disease: diagnosis and management | Q36400926 | ||
| Non-motor dysfunction in Parkinson's disease | Q36756269 | ||
| Norepinephrine: The redheaded stepchild of Parkinson's disease | Q36784705 | ||
| The premotor phase of Parkinson's disease | Q36903390 | ||
| Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory | Q36948136 | ||
| Non-motor symptoms in Parkinson's disease | Q37587798 | ||
| Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection | Q37686556 | ||
| Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease | Q38493912 | ||
| Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease | Q39124093 | ||
| Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration | Q39634067 | ||
| Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart | Q40026474 | ||
| Behavioural despair in rats: A new model sensitive to antidepressant treatments | Q40134604 | ||
| Glucagon-like peptide-1 prevents beta cell glucolipotoxicity | Q40565084 | ||
| Frontal lobe dysfunction in secondary depression | Q40582885 | ||
| Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. | Q40657491 | ||
| A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells | Q40748616 | ||
| Long-term regulation of serotonergic activity in the rat brain via activation of protein kinase A. | Q40872180 | ||
| Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disea | Q41158228 | ||
| 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor | Q41170164 | ||
| Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease | Q41346993 | ||
| Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons | Q42007296 | ||
| Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study | Q42455719 | ||
| Prolonged activation of cAMP-response element-binding protein and ATF-2 needed for nicotine-triggered elevation of tyrosine hydroxylase gene transcription in PC12 cells | Q42490271 | ||
| Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. | Q42524942 | ||
| Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. | Q42624819 | ||
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice | Q43018157 | ||
| Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine | Q43024089 | ||
| Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: an in vivo(1)H-MRS study at 9.4T. | Q43028260 | ||
| Rasagiline improves learning and memory in young healthy rats | Q43045852 | ||
| Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease | Q43156838 | ||
| Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits | Q43167027 | ||
| MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus | Q43197575 | ||
| Tryptophan depletion impairs object-recognition memory in the rat: reversal by risperidone | Q43204033 | ||
| Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease | Q43246435 | ||
| Is immobility of rats in the forced swim test "behavioral despair"? | Q43315896 | ||
| Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia | Q43651582 | ||
| SSRIs in the treatment of depression in Parkinson's disease | Q44467578 | ||
| Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats | Q44489178 | ||
| Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis | Q44535170 | ||
| Positron emission tomography of striatal serotonin transporters in Parkinson disease | Q44585433 | ||
| P433 | issue | 5 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 183-193 | |
| P577 | publication date | 2012-08-22 | |
| P1433 | published in | Neuropeptides | Q15751202 |
| P1476 | title | Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. | |
| P478 | volume | 46 |
| Q36538782 | Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma. |
| Q89563105 | Assessment of serotonergic system in formation of memory and learning |
| Q93094007 | Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat |
| Q49096857 | Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats. |
| Q37473323 | Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4. |
| Q38188177 | Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic |
| Q48164658 | Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial |
| Q50560411 | Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. |
| Q48254506 | GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats |
| Q91448321 | Glucagon-like peptide 1 (GLP-1) |
| Q61449892 | Glucose Homeostasis Is Not Affected in a Murine Model of Parkinson's Disease Induced by 6-OHDA |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q91143521 | Glutamatergic Alterations in STZ-Induced Diabetic Rats Are Reversed by Exendin-4 |
| Q38149622 | Incretin actions beyond the pancreas: lessons from knockout mice |
| Q51713596 | Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. |
| Q38807899 | Insulin resistance and Parkinson's disease: A new target for disease modification? |
| Q38105048 | Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions? |
| Q38668948 | Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases |
| Q90769540 | Protective Effects of Incretin Against Age-Related Diseases |
| Q90358913 | Recent Advances in Drug Repurposing for Parkinson's Disease |
| Q90264679 | Reduced Sensory-Evoked Locus Coeruleus-Norepinephrine Neural Activity in Female Rats With a History of Dietary-Induced Binge Eating |
| Q38708302 | Tactile learning in rodents: Neurobiology and neuropharmacology |
| Q50891658 | Temporal Dissociation of Striatum and Prefrontal Cortex Uncouples Anhedonia and Defense Behaviors Relevant to Depression in 6-OHDA-Lesioned Rats. |
| Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
| Q38275171 | The ongoing pursuit of neuroprotective therapies in Parkinson disease |
| Q98774928 | Therapeutic strategies for Parkinson's disease: promising agents in early clinical development |
Search more.